RECURRENT HAIRY CELL LEUKEMIA
Clinical trials for RECURRENT HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare leukemia: targeted pill tested in relapsed patients
Disease control Recruiting nowThis study tests a drug called venetoclax in 20 adults whose hairy cell leukemia has returned after previous treatment. The drug works by blocking a protein that cancer cells need to survive. The goal is to see how many patients respond and achieve complete remission.
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:23 UTC
-
New hope for hairy cell leukemia: targeted drug combo enters trials
Disease control Recruiting nowThis study tests a new combination of drugs (tovorafenib and rituximab) for people with classical hairy cell leukemia, a rare blood cancer. The first part includes patients whose cancer returned or didn't respond to prior treatment; the second part compares the new combo to stand…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:22 UTC
-
Promising combo may keep rare leukemia at bay
Disease control Recruiting nowThis study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive cladribine chemotherapy to kill cancer cells, then rituximab immunotherapy to clear any remaining disease. The goal is to improve complete remission rates and reduce the ch…
Matched conditions: RECURRENT HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC